

1 **Determinants of COVID-19 outcomes: A systematic review**

2 Shirley Crankson\*, Subhash Pokhrel, Nana Kwame Anokye  
3 Division of Global Public Health, Department of Health Sciences, College of Health,  
4 Medicine and Life Sciences, Brunel University London.  
5

6 **Abstract**

7 **Background:** The current pandemic, COVID-19, caused by a novel coronavirus SARS-CoV-  
8 2, has claimed over a million lives worldwide in a year, warranting the need for more  
9 research into the wider determinants of COVID-19 outcomes to support evidence-based  
10 policies.

11 **Objective:** This study aimed to investigate what factors determined the mortality and length  
12 of hospitalisation in individuals with COVID-19.

13 **Data Source:** This is a systematic review with data from four electronic databases: Scopus,  
14 Google Scholar, CINAHL and Web of Science.

15 **Eligibility Criteria:** Studies were included in this review if they explored determinants of  
16 COVID-19 mortality or length of hospitalisation, were written in the English Language, and  
17 had available full-text.

18 **Study appraisal and data synthesis:** The authors assessed the quality of the included studies  
19 with the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality  
20 checklist, depending on their study design. Risk of bias in the included studies was assessed  
21 with risk of bias assessment tool for non-randomised studies. A narrative synthesis of the  
22 evidence was carried out. The review methods were informed by the Joanna Briggs Institute  
23 guideline for systematic reviews.

24 **Results:** The review included 22 studies from nine countries, with participants totalling  
25 239,830. The included studies' quality was moderate to high. The identified determinants  
26 were categorised into demographic, biological, socioeconomic and lifestyle risk factors,  
27 based on the Dahlgren and Whitehead determinant of health model. Increasing age (ORs  
28 1.04-20.6, 95% CIs 1.01-22.68) was the common demographic determinant of COVID-19  
29 mortality while living with diabetes (ORs 0.50-3.2, 95% CIs -0.2-0.74) was one of the most  
30 common biological determinants of COVID-19 length of hospitalisation.

31 **Review limitation:** Meta-analysis was not conducted because of included studies'  
32 heterogeneity.

33 **Conclusion:** COVID-19 outcomes are predicted by multiple determinants, with increasing  
34 age and living with diabetes being the most common risk factors. Population-level policies  
35 that prioritise interventions for the elderly population and the people living with diabetes may  
36 help mitigate the outbreak's impact.

37

38 PROSPERO registration number: CRD42021237063.

39

## 40 **Strength and limitations of this review**

- 41 • This is the first systematic review synthesising the evidence on determinants of  
42 COVID-19 LOS outcome.
- 43 • It is also the first review to provide a comprehensive investigation of contextual  
44 determinants of COVID-19 outcomes, based on the determinants of health model;  
45 thus, presenting with crucial gaps in the literature on the determinants of COVID-19  
46 outcomes that require urgent attention.
- 47 • The review was restricted in conducting meta-analysis due to included studies'  
48 heterogeneity.
- 49 • The review focused on only papers published in the English Language; hence, other  
50 relevant papers written on other languages could have been omitted.

51

52

53

54

55

## 56 **Introduction**

57 COVID-19 (SARS-CoV-2, coronavirus) is currently among the leading causes of death  
58 globally. As of January 9th, 2021, 87,589,206 cases and 1,906, 606 deaths had been recorded  
59 globally (1). While its case fatality ratio (CFR) has been relatively low (CFR=2.2%),  
60 compared to CFRs of previous coronavirus outbreaks, notably, MERS (CFR=9.5%) and  
61 SARS-COV-1 (CFR=34.4%), its aggressive and alarming transmission rate has posed  
62 enormous challenges on global health (2). Even the current reported transmission rate of

63 COVID-19 may be lower than the actual transmission rate because a significant proportion of  
64 infected persons may remain undetected because they are asymptomatic (3). And regarding  
65 its CFR, current predictions even suggest that mortality ratio may increase since the  
66 pandemic is still ongoing (4). The infectivity and fatality rates associated with COVID-19,  
67 together with the worldwide panic it generates, make the current coronavirus pandemic a  
68 significant threat to public health, and its gargantuan impact unlike anything the world has  
69 experienced in the last two decades (5).

70

71 Since its inception, COVID-19 has overburdened the whole global health system, from  
72 crippling health resources to causing paradigm shifts in health care delivery (6). The testing  
73 process, quarantine and isolation associated with the virus has had dire psychological and  
74 financial implications on individuals and institutions (7). Furthermore, lockdowns instituted  
75 by affected countries to curb the virus's spread resulted in disrupted formal education,  
76 unplanned fiscal costs on emergency reliefs, and decreased productivity, all translating into  
77 huge economic costs to governments and organisations (8). The overall COVID-19 burden, in  
78 terms of health and fiscal implications, has been consequential in both high-income and low-  
79 and middle-income countries, albeit with contextual differences.

80 Regardless of the significant interventions to curb the virus's spread and subsequently reduce  
81 its severest outcome, i.e., mortality and morbidity, the outbreak continue to increase. As of  
82 January 9th, 2021, the daily global COVID death was 15,522, the highest daily mortality  
83 since the pandemic started, and about 3,000 more deaths since the first peak in daily COVID-  
84 19 deaths (initial peak April 17th – 12,511 daily deaths) (1). Also, 823,856 cases were  
85 confirmed on January 9th, 2021, representing a 0.93% increase from the previous day's case  
86 count. The rapid rise in the COVID-19 cases and deaths worldwide necessitates continuous

87 research on risk factors for COVID-19 outcomes to provide current evidence-based  
88 interventions to reduce the outbreak's drastic impact.

89

90 Several studies on determinants of COVID-19 outcomes were identified in the literature;  
91 however, most of them were primary studies investigating risk factors for COVID-19  
92 mortality (9, 10, 11). The few secondary studies/systematic reviews found in the literature  
93 encompassed only papers from high-income countries (12, 13). Also, there is inadequate  
94 coverage on other COVID-19 outcomes, specifically, length of hospital stay (LOS). Till date,  
95 no review has explored risk factors/determinants of COVID-19 LOS. Findings from such  
96 studies will be essential for help health systems to develop contingency plans for bed  
97 occupancy and health resources, especially with the swift increase in the COVID-19 cases.  
98 Thus, this study aimed to review factors that determine COVID-19 mortality and LOS in  
99 individuals diagnosed with COVID-19 to address the literature dearth and contribute to  
100 global efforts at curtailing the pandemic. Understanding the risk factors of COVID-19  
101 outcomes based on a comprehensive synthesis of global but rapidly emerging evidence might  
102 be useful to implement effective policies to address the disease burden.

## 103 **Methods**

### 104 **Search strategy**

105 From 21<sup>st</sup> to 31<sup>st</sup> December 2020, Scopus, Google Scholar, CINAHL and Web of Science  
106 databases were searched for relevant studies using the search terms: 'Determinants'  
107 'Predictors' 'COVID-19' 'SARS-CoV-2' 'Mortality' 'Length of hospital stay' 'Length of  
108 hospitalisation'. The search terms were combined with mesh words and Boolean operators to  
109 ensure sensitive and targeted search. Full search strategy is shown in supplementary

110 information 1. First screening of the databases results was conducted independently by two of  
111 the reviewers (SC and NKA) to ensure their relevance to this study. The titles and abstract of  
112 the identified relevant studies were screened against this review's eligibility using the  
113 following predetermined eligibility criteria: population - individuals diagnosed with COVID-  
114 19, exposures – demographic, socioeconomic, lifestyle, environmental biological/medical  
115 factors, outcome – COVID-19 related mortality and LOS, studies that explored determinants  
116 of COVID-19 mortality and LOS in participants with COVID-19, studies whose LOS  
117 endpoint was discharge or death, and not hospital transfers, studies written and published in  
118 the English Language, and with full-text available. No date restriction was applied in any of  
119 the databases since most COVID-19 studies are recent. No database filters were also applied.  
120 The references of the identified papers were also tracked for papers eligible for this  
121 review. Any disagreements relating to studies' screening was discussed and resolved with the  
122 third reviewer (SK) and

123

## 124 **Data extraction**

125 Two of the authors (SC and NKA) extracted the relevant data from the included studies using  
126 a comprehensive a priori developed set of data extraction questions (Supplementary  
127 information 2), informed by the JBI data extraction tools. The questions were categorised  
128 under two main themes, i.e., general information (authors name, study settings, study aim,  
129 year of publication) and methodology (sample size, sample characteristics, outcomes etc.), to  
130 ensure the sensitivity of the questions to the overarching objectives of this review. The data  
131 extraction questions were piloted-tested on five selected studies before their final usage. The  
132 third author (SP) randomly selected and reviewed 50% of the extracted data from the

133 included studies to ascertain data extraction quality. Finally, all disagreements were resolved  
134 by consensus.

135

## 136 **Risk of bias and quality assessment**

137 The Newcastle-Ottawa Scale (NOS) and the Agency for Healthcare Research and Quality  
138 (AHRQ) appraisal checklist were used to appraise the quality of the included studies. These  
139 checklists were based on a systematic review's recommendation (14). The NOS provides  
140 eight items grouped under three main domains: the selection of cohorts, the comparability of  
141 cohorts, and outcomes assessment. A star (\*) was awarded if a study met an item under the  
142 three defined domains. A maximum of one star was given to items within the selection and  
143 outcome domain, and a maximum of two stars was given to the item under the comparability  
144 domain. Thus, studies with nine stars were rated as high-quality study and those with two  
145 stars or less were graded as low quality. Like the NOS, the ARHQ also provides  
146 items/checklists (n=11) for assessing the quality of the study's' methods and outcomes. A  
147 'yes', 'no' or 'not applicable (NA)' was used to indicate whether a study met the AHRQ  
148 requirement. The number of 'yes' from a study represented the study's quality. Consequently,  
149 studies with eleven 'yes', suggesting 11 total scores, were ranked as high quality, whereas  
150 those with two or less 'yes' were rated as low quality. Also, risk of bias assessment of both  
151 the study and outcome level of the included papers was performed with risk of bias  
152 assessment tool for non-randomised studies. The quality and risk assessment findings are  
153 presented in supplementary information 3.

154

## 155 **Data synthesis**

156 Descriptive data synthesis, informed by the JBI manual for evidence synthesis in systematic  
157 reviews was conducted to comprehensively describe the methods, findings, and quality of the  
158 included studies (15). The studies' methods, its operationalisation and the subsequent  
159 findings were compared across the papers to identify common determinants of COVID-19  
160 mortality and LOS. Also, the range of effect sizes (odds ratios/hazard ratios) of the identified  
161 determinants in the studies were synthesised to understand the magnitude of the effect on the  
162 study outcomes. This was done by reporting the lowest and highest effect sizes from studies  
163 that identified common determinants.

164

## 165 **Patient and public involvement**

166 This study reviewed already published and available research. Therefore, no patients or the  
167 public were directly involved in this review process. The findings of this review will be  
168 shared publicly through scientific publication, social media, and conference presentations.

169

## 170 **Results**

### 171 **Search result**

172 The database search yielded 1,653 studies. The authors removed 11 duplicates and eliminated  
173 a further 1,564 after title screening for relevance to this review. The abstracts of the  
174 remaining 78 studies were assessed for eligibility using the predetermined eligibility criteria.  
175 Twenty-two studies met the inclusion criteria and were subsequently included in this review,  
176 as shown in the Prisma flow diagram below (Fig 1).

177

178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205




Fig 1. Prisma flow diagram showing the literature search.



## 206 **Overview of included studies**

207 The studies spanned nine major countries, of which eight were high-income countries and  
208 one upper-middle-income country. Majority of them were from China (n=6) and USA (n=6),  
209 followed by Spain (n=2), and England (n=2), and one each from Kuwait, Mexico, France,  
210 Italy, Austria, and one multi-continent study- participants from Africa, Europe, Australia,  
211 Asia, and Americas (16). They all used the quantitative research approach, with retrospective  
212 cohort design as the predominant study design (n=12). Most of them (n=20) accessed only  
213 secondary data, retrieved mainly from the patients' electronic medical records. The remaining  
214 two used both secondary and primary data (face to face and telephone interviews) (10, 17).

215 The studies sample size ranged from 58 to 177,133, totaling 239,830 participants. All the  
216 studies included both male and female participants; however, the men dominated,  
217 representing 51.4% of the studies' entire population. Only 7 studies were age-specific -  
218 limited their inclusion to participants  $\geq 18$  years old. The majority (n=20) included only  
219 persons with confirmed COVID-19 test, either through the reverse transcription-polymerase  
220 chain reaction (RT-PCR) or nasopharyngeal swabs. The other two studies included all  
221 confirmed, negative, and suspected, and both suspected and confirmed COVID-19 cases (18,  
222 19) (Table 1). The studies' quality on the NOS and AHRQ ranged from 6-9, representing  
223 moderate to high quality and the common risk of bias across the studies was the inability to  
224 control the influence of unmeasured confounders. This confounding bias inherently  
225 influenced the studies' findings and could subsequently affect this review's finding.

226

227 Of the COVID-19 outcomes, 19 studies focused on only COVID-19 mortality, 2 solely on  
228 COVID-19 LOS and 1 on both COVID-19 mortality and LOS. Mortality was generally  
229 described as either in-hospital deaths, i.e., deaths occurring in a hospital or all-cause

230 mortality, i.e., all deaths in COVID-19 patients, regardless of the cause. LOS was also  
231 defined commonly as the number of days in hospital admission due to COVID-19. One study  
232 described it as normal or prolonged, based on their measured average LOS (<17 days –  
233 normal; >17 - prolonged) (20). Consequently, they assessed LOS as a binary outcome. On the  
234 determinants of COVID-19 outcomes, identified risk factors were categorised into  
235 demographic, lifestyle, socioeconomic and biological/medical determinants, based on the  
236 determinants of health model (21). The rationale was to provide contextual analysis and  
237 identify common risk factors for COVID-19 outcomes. The biological/medical determinants  
238 encompassed as comorbidities, laboratory findings, and participants symptoms. The findings  
239 of the studies are synthesised below (Table 2).

240 Table 1: Study characteristics

Studies	Aim	Settings	Sample size	Sample characteristics	Study outcomes (definition)
Alaa et al. (2020) (22)	To investigate the influence of timing of hospital admission on risk of mortality for patients with COVID-19 in England	England	6068	Individuals with COVID-19 in the CHES database during the study period. Average age – 68 years, Men – 61%	Mortality (all cause-mortality)
Almazeedi et al. (2020) (23)	To examine the demographics, clinical manifestations, and outcomes in patients with COVID-19	Kuwait	1096	All COVID-19 patients admitted to Jaber Al Ahmad Al-Sabah hospital in Kuwait, with COVID-19 diagnosis based on WHO guideline and confirmed Polymerase Chain Reaction (PCR) test. Average age – 41 years, Men – 81%.	Mortality (in-hospital mortality)
Bello-Chavolla et al. (2020) (18)	To examine the association between diabetes and SARS-CoV-2 infection and its consequent clinical outcomes	Mexico	177,133	All confirmed, negative, and suspected COVID-19 cases in the Mexican MOH dataset. Average age – 46.7 years, Men – 57.7%	Mortality
Berenguer et al. (2020) (11)	To examine the predictors of death in patients with COVID-19 in Spain	Spain	4035	Males (61%) and females (39%) with COVID-19 confirmed by real-time PCR assay in 127 Spanish centres. Average age – 70 years, Men – 61%	Mortality (all-cause mortality)

Carrasco-Sánchez et al. (2020) (24)	To examine the association between blood glucose levels and in-hospital mortality in non-critically patients with COVID-19.	Spain	11,312	Patients $\geq 18$ years with COVID-19 confirmed by Reverse Transcription (RT)-PCR and hospitalized from 1 March 2020 to 31 May 2020. Average age – 67.06 years, Men – 57.1%	Mortality (all-cause mortality during hospitalization)
Halalau et al. (2020) (25)	To provide risk assessment tools for patients with COVID-19.	USA	2025	Patients with positive COVID-19 on nasopharyngeal swabs at any Beaumont Health’s eight emergency departments between 1 March 2020 and 1 April 2020. Men – 53.7%	Mortality (in-hospital mortality)
Kaeuffer et al. (2020) (26)	To explore risk factors of severe COVID-19 disease and mortality	France	1,045	Individuals $\geq 18$ years with confirmed COVID19, hospitalized in Strasbourg and Mulhouse hospitals - March 2020. Average age – 66 years, Men – 69%	Mortality (in-hospital mortality)
Li et al. (2020) (10)	To investigate severity of COVID-19 outcomes	China	548	Individuals with COVID-19 admitted to Tongji Hospital from 26 January – 5 February 2020. Men – 50.9%.	Mortality (in-hospital mortality)
Okoh et al. (2020) (27)	To examine the clinical features of COVID-19 outcomes in Black/African American and Latino Hispanic	USA	251	Adults $\geq 18$ -years admitted between March 10 and April 10, 2020. Men – 51%	Mortality (in-hospital death)
Petrilli et al.	To explore in-hospital COVID-	USA	5279	Laboratory confirmed COVID-19 patients with	Mortality

(2020) (28)	19 outcomes.			average age of 54. Men – 49.5%	
Sourij et al. (2020) (29)	To investigate predictors of in-hospital COVID-19 mortality in patients with prediabetes and diabetes.	Austria	238	People $\geq 18$ years with confirmed COVID-19 and a with type 1 diabetes, type 2 diabetes, or prediabetes from 10 hospital sites in Austria. Average age – 71.1 years, Men – 63.6%	Mortality (in-hospital deaths)
Wang et al. (2020) (30)	To examine the characteristics and prognosis of COVID-19 infections	China	293	Patients with COVID-19 diagnosis based on the NHC- China formulated “Diagnosis and treatment of novel coronavirus pneumonia” Men – 47.1%	Mortality
Zhang et al. (2020) (31)	To examine the influence of D-dimer levels on COVID-19 mortality	China	343	Adults $\geq 18$ years with laboratory-confirmed COVID-19 between 12 January and 15 March 15. Average age – 62 years, Men – 49.3%	Mortality (in-hospital mortality)
Zhou et al. (2020) (9)	To investigate in-hospital COVID-19 risk factors.	China	191	$\geq 18$ years old adult inpatients with laboratory confirmed COVID-19 from Jinyintan and Wuhan Pulmonary Hospital. Men – 62%	Mortality (in-hospital death)
Tartof et al. (2020) (19)	To determine the association between BMI and COVID-19 mortality.	USA	6916	Patients with COVID-19 from 13 February - 2 May 2020 from health care organisations located throughout 9 counties in Southern California. Men – 45%	Mortality (in-hospital death)
Williamson et al. (2020)	To investigate risk factors of COVID-19 mortality.	England	10,926	$\geq 18$ years individuals with COVID-19 and currently registered as active patients in GP	Mortality (COVID-19 related death)

(32)					surgery. Men –49.9%	
Grasselli et al. (2020) (17)	To determine risk factors associated with COVID-19 ICU mortalities.	Italy	3988	Critically ill patients with laboratory-confirmed COVID-19. Average age - 63 years, males- 79.9%	Mortality (COVID-19 death)	
Mikami et al. (2020) (33)	To examine factors associated with COVID-19 mortality.	USA	6493	Patients with laboratory confirmed COVID-19 with from one of the 8 hospitals in New York City metropolitan. Average age 59 years, males - 54.5%	Mortality (in-hospital mortality)	
Albitar et al. (2020) (16)	To explore predictors of COVID-19 mortality among patients from worldwide open access data	Africa Asia America Australia Europe	828	COVID-19 patients with definite outcomes. Average age - 49.4 years, male majority – 59.1%, and majority located in Asia – 69.3%	Mortality)	
Wu et al. (2020) (34)	To examine factors associated with longer length of COVID-19 hospital stay	China	58	Patients with COVID-19 and hospitalised in Qiaokou Fangcang Hospital. Average age – 55.5 years, Men – 37.9%	LOS (number of days spent on admission)	
Guo et al. (2020) (20)	To investigate determinants of COVID-19 prolonged hospital length of stay	China	75	Patients with laboratory-confirmed COVID-19 and discharged from 20 January – 16 March 2020. Average age – 47 years, Men – 57%	LOS (<17 days median Los-normal; >17days median Los prolonged)	

Mendy et al. (2020) (35)	To identify factors associated with COVID-19 hospitalization and mortality among ethnically diverse cohort.	USA 689	Patients with COVID-19 confirmed with a RT-PCR from the University of Cincinnati health system between 13 March – 31 May 2020. Average age – 49.5 years, Men – 53%	Mortality: (COVID-19 death during hospitalisation). LOS: (number of days hospitalised)
--------------------------	---	---------	--	---

241  
242  
243  
244  
245  
246  
247  
248  
249  
250

251 Table 2: Synthesised review findings

Variable category	Determinants	Variable description	No. of studies reporting sign. with COVID-19	Range of effect sizes HR/OR/AOR/ $\beta$ 95% C.I.
-------------------	--------------	----------------------	--	---

			mortality	Low high	high	low
Demographic variables	Age (older/increasing)	Years lived	16(16[+], 0[-])	1.04	20.6	1.01
	Sex/gender (male)	Male or female	8(8[+], 0[-])	1.15	1.70	1.00
	Geographic location (America)	Africa/Asia/Australia/America/Europe	7.44	2.80	3.55	15.62
Biological/medical variables	CKD (present)	Present or not	5(5[+], 0[-])	1.99	4.48	1.09
	C-reactive protein (elevated- >5mg/L)	Level of C-reactive protein in blood	4(4[+], 0[-])	11.08	1.01	2.00
	Diabetes (present)	Present or not	6(6[+], 0[-])	3.20	1.18	12.23
	Hypertension (present)	Present or not	4(4[+], 0[-])	36.72	1.14	3.58
	Dyspnoea (present)	Present or not	3(3[+], 0[-])	7.55	1.45	2.1
	Cancer (present)	Present or not	3(3[+], 0[-])	3.4	1.3	2.46
	COPD (present)	Present or not	3(3[+], 0[-])	2.95	1.27	1.68
	Coronary heart disease (present)	Present or not	2(2[+], 0[-])	2.19	1.77	2.14
	BMI (obesity)	Normal weight/overweight/obese	4(4[+], 0[-])	17.79	1.25	4.18
	Asthma (present)	Present or not	2(2[+], 0[-])	8.26	1.55	4.29
	D-dimer ( $\geq 2.0$ $\mu\text{g/ml}$ )	Present or not	2(2[+], 0[-])	23.44	1.19	22.4
				175.7		1.02



252

	Hospitalisation before onset of COVID-19 symptoms	Time of admission relative to symptom onset	1(0[+], 1[-])	0.52 0.61	0.45	
Lifestyle variables	Smoking (current smoker)	Smoker or non-smoker	2(2[+], 0[-])	0.89 10.09 83.40	0.28	
Socioeconomic variables	Index of multiple deprivation (greatest)	Least to greatest	1(1[+], 0[-])	1.79 1.91	1.68	
Variable category	Determinants	Variable description	No. of studies reporting sign. with COVID-19 LOS	*Range of effect sizes HR/OR/AOR 95% C.I.		
Demographic variables	Sex (Male)	Male or female	2(1[+], 1[-])	0.19	0.39	0.05 0.63
Biological variables	Diabetes (present)	Present or not	2(2[+], 0[-])	0.50	3.2	-0.2 0.74
	Fever (present)	Present or not	2(2[+], 0[-])	3.5	8.27	1.39 72.16
	Bilateral pneumonia (present)	Present or not	1(1[+], 0[-])	3.4		0.49 6.25
	CKD	Present or not	1(1[+], 0[-])	3.73		1.95 145.4
	COPD	Present or not	1(1[+], 0[-])	0.45		0.11 0.79
	Asthma	Present or not	1(1[+], 0[-])	0.50		0.20 0.81

253 Age and sex were the common demographic risk factors. Of the 20 studies on age and  
254 COVID-19 mortality, 16 identified increasing age as a significant determinant of COVID-19  
255 mortality, with effect sizes ranging from 1.04 to 20.6 and 95% CI from 1.01 to 22.68 (9, 10,  
256 11, 16, 17, 18, 24, 25, 26, 27, 28, 29, 30, 32, 33, 35). Also, 8 of the 20 studies on gender/sex  
257 and COVID-19 found men to have a higher risk of COVID-19 mortality than women (10, 11,  
258 16, 17, 24, 26, 28, 32). On LOS, 2 of the 3 studies assessing LOS found women (AOR=0.19,  
259 95%CI=0.05-0.63) (20) and men ( $\beta=0.39$ , 95% CI=0.16-0.62) (35) as determinants of  
260 COVID-19 duration of hospitalisation.

261

262 Of biological/medical risk factors, the review identified diabetes (n=6), Chronic kidney/renal  
263 disease (CKD) (n=5), hypertension (n=4), C-reactive protein (CRP) (n=4), BMI (n=4),  
264 dyspnoea (n=3), COPD (n=3), cancer (n=3), coronary heart disease (n=2), asthma (n=2) and  
265 D-dimer (n=2) as determinants of COVID-19 mortality. Of the 10 studies that included CKD  
266 in their analysis, 5 found it a significant determinant of COVID-19 mortality (18, 25, 26, 30,  
267 35). Additionally, out of the 5 studies that investigated the influence of CRP on COVID-19  
268 mortality, 4 showed that elevated CRP in the blood (at least >5mg/L) increases the risk of  
269 COVID-19 death (11, 24, 26, 29). Also, people with diabetes were found to have a higher  
270 risk of COVID-19 mortality in 6 of the 18 studies on diabetes and COVID-19 mortality (16,  
271 17, 18, 26, 30, 32)

272 Like diabetes, hypertension was also identified as a determinant of COVID-19 mortality in 4  
273 out of the 16 studies (11, 16, 24, 30). Furthermore, 4 of 11 studies on BMI and COVID-19  
274 mortality showed that obesity significantly determines COVID-19 mortality (11, 18, 19, 32).  
275 For LOS, fever and diabetes were associated with prolonged LOS (43,35).

276

277 On lifestyle factors, smoking was the only assessed determinant of COVID-19 outcomes. It  
278 was identified as a risk factor for COVID-19 mortality in 2 of the eleven studies that explored  
279 it, with effect size ranging from 0.89-10.09, 95% CIs from 0.28-83.40 (23, 32). None of the  
280 studies on LOS reported a significant association between smoking and COVID-19 LOS.  
281 Finally, the only study on socioeconomic determinants and COVID-19 reported that greater  
282 deprivation determines COVID-19 mortality (HR=1.79, 95% 1.68 – 1.91) (32)

283  
284  
285  
286

## 287 **Discussion**

288 This review aimed to investigate the determinants of COVID-19 outcomes. The review found  
289 that the specification and subsequent analysis of most of the determinants differed across the  
290 studies. For example, Berenguer et al. (2020) described elevated C-reactive protein (CRP) as  
291 CRP>5mg/L, while Carrasco-Sánchez et al. (2020) described it as >60mg/L. Also, whilst  
292 Almazeedi et al. (2020) and Sourij et al. (2020) assessed CRP as a continuous variable,  
293 Kaeuffer et al. (2020) categorised it into two groups: CRP- 100-199mg/L and CRP≥200mg/L.  
294 Like CRP, older age was also specified differently across the studies. Bello-Chavolla et al.  
295 (2020) and Li et al. (2020) described it as individuals ≥65 years, Zhang et al. (2020) termed it  
296 as persons >65 years while Petrilli et al. (2020) defined it as people ≥75 years. Apart from  
297 these variations, the study settings also differed across the papers. These contextual  
298 differences, which could include disparities in access to healthcare, crowded living, could  
299 have inherently influenced the studies' findings (36).  
300 Despite these heterogeneities, the result of some of the determinants was similar across the  
301 studies. For instance, the significant association between age and COVID-19 mortality was

302 reported across sixteen out of twenty papers, and four out of five articles examining CRP also  
303 showed a significant association between CRP and COVID-19 mortality. Regardless of the  
304 differences in methods, these findings could have public health implications for populations  
305 worldwide (37). Thus, they can be considered during the planning and implementation of  
306 effective policies for COVID-19.

307 Nonetheless, there were other contrasting findings. For example, Mendy et al. (2020)  
308 indicated that men are more likely to stay longer in hospitals due to COVID-19 than women.  
309 Conversely, Guo et al. (2020) showed that women are more associated with prolonged  
310 COVID-19 hospitalisation than men. Both studies had men dominating their study  
311 participants, 53% and 57% respectively; but the proportion of men in Guo et al. (2020) were  
312 marginally higher. However, in absolute figures, Mendy et al. (2020) included more male  
313 participants (n=365) than Guo et al. (2020) (n=43). Therefore, these sample size variations  
314 could account for the differences in their sex and LOS findings due to COVID-19. Moreover,  
315 these findings are from only two studies; thus, they may not be enough to conclude the  
316 association between sex and COVID-19 LOS. Further discussions on the review findings,  
317 based on the determinants of health model, are provided below.

318

## 319 **Demographic determinants of COVID-19 outcomes**

320 The underlying mechanism for the association between older age and COVID-19 mortality is  
321 unclear; however, several studies indicate that decrease in immune responses coupled with  
322 increase comorbid burden with ageing may account for this observation (9, 38, 39). Another  
323 study further explained that age-related changes or defects in the immune system, particularly  
324 significant defect in cell-mediated immunity, primarily affects immune responses to diseases  
325 (40). Also, evolution and ageing theories, like the antagonistic pleiotropy theory, postulate  
326 that even beneficial genes at an early age may be less efficient or deleterious with increasing

327 age, and this may inherently increase susceptibility to previously shielded diseases (41, 42).  
328 Moreover, current evidence suggests that increasing age is a common risk factor for several  
329 health outcomes, like mortalities and morbidities (43-46).

330

331 Even though ageing generally decreases immune responses to diseases and infections, the  
332 innate human response is mostly safeguarded (40). Thus, many individual and environmental  
333 factors may account for the relationship between ageing and disease outcomes, such as  
334 COVID-19 mortality. These factors may include nutritional deficiencies, decreased  
335 functionality, exposure to pathogens, vaccinations, an individual's lived experiences and  
336 genetic make-up and access to health care (47). Furthermore, there are reports on good  
337 COVID-19 prognosis in elderly patients (48). Therefore, it may be imperative to understand  
338 how these factors cumulatively affect the immune system, and further mediate ageing and  
339 decreased immune system relationship to provide exhaustive literature on the subject. Other  
340 studies have also reported severe COVID-19 consequences in children (49, 50).  
341 Consequently, there is a need for studies to focus more on children, as much as they have on  
342 the adult population to offer a balanced argument to inform COVID-19 and ageing policies.

343

344 Like ageing, studies also attribute the sex disparities regarding COVID-19 mortality to sex-  
345 based differences in immunological responses to viral infections (51, 52). The X sex  
346 chromosome has encoded immune regulatory genes that decrease viral infections'  
347 susceptibility (51). Since women have twice X-chromosomes to men, they tend to have  
348 higher innate immunity to viral infections, like COVID-19, and by extension a lower risk of  
349 severe COVID-19 outcomes than men (51, 53). Similarly, in contrast to oestrogen,  
350 testosterone has an immunosuppressive effect; so, it attenuates men's immune responses to  
351 viral infections (54). Additionally, it is reported that men are genetically more predisposed to

352 produce higher levels interleukin (IL)-6, which are unfavourable to longevity, compared to  
353 women (55). Apart from these biological reasons accounting for the sex differences in  
354 COVID-19 mortality risk, behavioural and lifestyle factors like smoking and alcohol  
355 consumption, have been implicated in the gender disparities in COVID-19 outcomes. Data  
356 indicate that men are more likely to engage in these lifestyle factors that increase the risk of  
357 COVID-19 deaths than women (52). Women are more likely to comply with COVID-19  
358 precautionary measures than men and are more likely to remain confined than men (56).  
359 Regarding LOS, the evidence is not enough to indicate whether sex determines longer  
360 COVID-19 hospitalisation.

361

## 362 **Biological/medical determinants of COVID-19 outcomes**

363 The biological/medical determinants in this review were comorbidities, symptoms, and  
364 laboratory findings of the included studies participants. The biological determinants of  
365 COVID-19 outcomes included CKD, C-reactive protein, diabetes, hypertension, obesity,  
366 cancer, COPD, dyspnea, asthma, and coronary heart disease. Clinical data reveal that chronic  
367 conditions, such as the above, decrease innate immune responses in humans (57, 58). For  
368 instance, metabolic diseases/disorders, like diabetes, attenuates immunity and increase risk to  
369 infections by weakening lymphocyte and macrophage activities (59). Moreover, these chronic  
370 conditions are associated with increase pro-inflammatory cytokines resulting from  
371 dysregulation of systems, like the hypothalamic-pituitary-adrenal and sympathetic nervous  
372 system (58, 60). The accumulation of pro-inflammatory cytokines subsequently impairs  
373 systemic and cellular immune functions (57, 61).

374

375 Furthermore, studies hypothesize that the use of renin-angiotensin-aldosterone system  
376 (RAAS) inhibitors, like angiotensin-converting enzyme-2 (ACE-2), in the management of  
377 some of these chronic conditions increase COVID-19 infectivity (62, 63). This is because  
378 ACE2 also functions as a receptor for the COVID-19 virus (64). This RAAS and ACE-2  
379 hypothesis recently sparked debate and discourse on gold standard medical management of  
380 comorbidities in COVID-19 patients. One study indicated that sudden discontinuation of  
381 ACE-2 might have far worse consequences for high-risk-COVID-19 patients, particularly  
382 those with cardiovascular conditions, like myocardial infarction (65). Their argument is  
383 hinged on the paucity of human studies to corroborate the RAAS and ACE-2 theory.  
384 Additionally, experimental studies in mice showed that ACE-2 downregulation facilitates  
385 lung injuries and increases viral loads (60, 66). Thus, several human studies are needed to  
386 substantiate the harmful effect, or otherwise, of RAAS inhibitors in the management of  
387 COVID-19 patients with comorbidities.

388

### 389 **Lifestyle determinants of COVID-19 outcomes**

390 The included studies examined only smoking as a lifestyle determinant of COVID-19  
391 mortality. The association between smoking and COVID-19 mortality is biologically  
392 plausible because smoking is a risk factor for several conditions, like coronary heart disease  
393 and Chronic Obstructive Pulmonary Disease (COPD), that are associated with severe  
394 COVID-19 outcomes (67). Also, a cohort study with an average of 9.6 years follow-up by  
395 showed that 11% (men) and 13% (women) of pneumonia and COPD deaths were attributable  
396 to smoking (68). Additionally, the Centre for Disease Control and Prevention (CDC) also  
397 report that smoking is associated with about 113,000 respiratory deaths each year in the  
398 United States (69). Since COVID-19 is a respiratory infection and based on the above

399 evidence on smoking-related respiratory deaths, it may be reasonable to make projections that  
400 smoking may be significantly associated with severe COVID-19 outcomes.

401 Furthermore, data shows that smokers have increased upregulation or expression of ACE-2,  
402 the reported enzyme receptor for SARS-CoV-2 (COVID-19) (70), which may increase their  
403 risk of severe COVID-19 outcomes compared to non-smokers. A single-cell sequencing  
404 experiment further demonstrated that cigarette smoking upregulates ACE-2 in humans' lungs  
405 and increases their susceptibility to COVID-19 infections (71). They inferred that smoking  
406 cessation could reduce ACE-2 expression and thereby reduce the risk of COVID-19 disease.  
407 Thus, their findings advance the above argument on the benefit or otherwise of ACE-2  
408 dysregulation in humans in reducing the burden of COVID-19. Consequently, systematic  
409 reviews and meta-analyses of several high-quality studies on ACE-2 and COVID-19 are  
410 required to provide empirical evidence to inform policy and clinical practice. All the same,  
411 this review is limited in drawing a meaningful conclusion on the association between  
412 smoking and COVID-19 mortality because only one of the included studies identified  
413 smoking as a risk factor of COVID-19 mortality.

414

## 415 **Policy implications**

416 This review findings re-enforce the need for health systems to continue the testing, tracing,  
417 and isolation policies to reduce the spread of the virus and subsequently decrease the burden  
418 of the pandemic, particularly for high-risk individuals identified in this review. Additionally,  
419 countries, such as Nigeria, that are yet to implement crucial public health policies, like  
420 immunisation and routine COVID-19 testing, can draw lessons from countries like the UK  
421 that have benefited immensely from such policies. Although this may come with increased  
422 direct costs, especially the cost of PPEs and testing equipment, the indirect benefits to



423 populations, such as reduced disease burden and improved productivity, might be enormous  
424 for these countries.

425 However, lockdown policies, which seems to be the go-to policy for most countries, must be  
426 evaluated holistically, to ascertain their overall benefits, especially as the pandemic continues  
427 to rage. Evidence shows that lockdowns are beneficial when introduced at an earlier stage of  
428 an outbreak than later. For example, evaluating the national lockdown response in Norway,  
429 USA, Argentina, and the UK shows that the lockdown's timing and not the lockdown itself  
430 significantly reduced the burden of the outbreak in Argentina and Norway compared to the  
431 UK and the USA. For instance, the UK suffered significant health and economic recession  
432 due to the delays in the lockdown response to the viral outbreak. Their delay in implementing  
433 the first lockdown resulted in several other lockdowns that have had further economic  
434 implications. Therefore, lockdowns must be implemented earlier to prevent dire health and  
435 economic consequences.

436 Even the timing of lockdowns alone may not be enough to radically reduce viral transmission  
437 rate and consequently limit the probability of infections in high-risk individuals because data  
438 from other jurisdictions that introduced earlier national lockdowns, like Ghana, showed a  
439 steady increase in transmissions during the lockdown and a rapid rise few weeks post  
440 lockdown. Also, it is still crippling with the lockdown induced economic downfall. This  
441 suggests that lockdowns as single policies may be ineffective in plummeting COVID-19  
442 infections, mortalities, and financial hardships. Consequently, global health systems must  
443 also place a premium on other equally important policies, like robust testing and tracing.  
444 Currently, most countries do not conduct follow-up COVID-19 testing following negative  
445 test results at entry borders. A negative test result on arrival at entry borders may not be  
446 enough to declare individuals as virus-free since it can take fourteen days maximum for the  
447 virus to be detected, per the WHO guidelines. Thus, governments must apply both on arrival

448 and fourteen days post border arrival COVID-19 testing to ensure comprehensive  
449 identification of all positive cases to curtail the virus's potential spread.

450 Additionally, it will be crucial for countries, like the USA and Brazil, to implement the  
451 fourteen-day quarantine policies for all border entries, as it has shown to be effective  
452 reducing the COVID-19 impact in places like Argentina. Countries with partial quarantine  
453 policies, such as Ghana, will benefit from instituting mandatory quarantine for all border  
454 arrivals at government selected facilities since self-isolation education and passenger locator  
455 forms may be inadequate in reducing the viral spread. Furthermore, health systems must  
456 continuously promote behavioural change interventions to establish significant control over  
457 the viral outbreak. Enforcing compliance to behavioural change interventions, like social  
458 distancing, nose mask use, social hand washing and cough etiquette, can be the significant  
459 catalyst needed to decrease the pandemic's impact. Finally, the continuous increase in the  
460 COVID-19 cases and mortality indicate the need for an urgent review of current health  
461 policies at both international and national levels to implement suitable context-specific  
462 interventions to mitigate the COVID-19 menace effectively.

463

464 Concerning this study's strength, this is the first systematic review synthesising the evidence  
465 on LOS determinants, to the best of the researchers' knowledge. Therefore, it presents novel  
466 findings that could initiate useful interventions to address the burden of prolonged  
467 hospitalisation associated with COVID-19. It could also cause a paradigm shift and ensure  
468 holistic research coverage on all COVID-19 outcomes. Moreover, this is the first review to  
469 provide a comprehensive investigation of contextual determinants of COVID-19 outcomes,  
470 based on the determinants of health model. It identified crucial gaps in the literature on the  
471 determinants of COVID-19 outcomes that require urgent attention. Additionally, this review

472 evaluated current public health policies and suggested strategies to augment area-specific  
473 efforts at curbing the COVID-19 problem. Regarding limitations, the review was restricted in  
474 conducting further analysis, specifically, meta-analysis, to precisely estimate the associations'  
475 effect size due to included studies' heterogeneity. Also, most of the included studies (n=12)  
476 used retrospective design, thus, there was the possibility of residual confounders that could  
477 influence this review's findings. Additionally, all of them used secondary data from medical  
478 records of participants. Therefore, any omission or data entry error could affect their results  
479 and this review. Hence, caution must be taken when interpreting the findings of this review.

480

481

## 482 **Conclusion and recommendations**

483 This study's overarching aim was to examine the determinants of COVID-19 outcomes. The  
484 review findings showed that increasing age and comorbidities are more likely to determine  
485 COVID-19 outcomes. Thus, policies, like routine COVID-19 testing and prioritised  
486 vaccination to shield these high-risk individuals, must be sustained and extended to other  
487 populations yet to implement such important policies. Most importantly, health systems must  
488 continually review existing policies to ensure their context-specific relevance, especially with  
489 the emergence of a new viral variant and the rapid surge in cases. Based on this review, the  
490 authors recommend that future studies also focus on determinants of COVID-19 LOS.  
491 Additionally, studies should explore the determinants of COVID-19 outcomes in low-  
492 income-countries to ensure holistic and context-specific evidence on risk factors of COVID-  
493 19 mortality in the literature.

494

495

496

497

## 498 REFERENCES

- 499 1. WHO. Coronavirus Disease (COVID-19) Dashboard. 2021. Available from:  
500 <https://covid19.who.int/>. (Accessed on 10/01/2021).
- 501 2. Azamfirei R. The 2019 novel coronavirus: a crown jewel of pandemics? The Journal  
502 of Critical Care Medicine. 2020 Jan 31;6(1):3-4.
- 503 3. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K. et al.  
504 Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).  
505 International journal of infectious diseases. 2020 May; 94:154.
- 506 4. Yuan J, Li M, Lv G, Lu ZK. Monitoring transmissibility and mortality of COVID-19  
507 in Europe. International Journal of Infectious Diseases. 2020 Jun 1; 95:311-5.  
508 <https://doi.org/10.1016/j.ijid.2020.03.050>.
- 509 5. Promislow DE. A geroscience perspective on COVID-19 mortality. The Journals of  
510 Gerontology: Series A. 2020 Sep;75(9): e30-3.  
511 <https://doi.org/10.1093/gerona/glaa094>.
- 512 6. Maia Chagas A, Molloy JC, Prieto-Godino LL, Baden T. Leveraging open hardware  
513 to alleviate the burden of COVID-19 on global health systems. PLoS biology. 2020  
514 Apr 24;18(4): e3000730.
- 515 7. Ornell F, Schuch JB, Sordi AO, Kessler FH. “Pandemic fear” and COVID-19: mental  
516 health burden and strategies. Brazilian Journal of Psychiatry. 2020 Jun;42(3):232-5.
- 517 8. Amponsah R, Frimpong IA. Ghana in the Face of COVID-19: Economic Impact of  
518 Coronavirus (2019-NCOV) Outbreak on Ghana. Open Journal of Business and  
519 Management. 2020 Jun 17;8(04): 1404.  
520 <http://www.scirp.org/journal/Paperabs.aspx?PaperID=100937>.
- 521 9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. et al. Clinical course and risk factors for  
522 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort  
523 study. The lancet. 2020 Mar 28;395(10229):1054-62.
- 524 10. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y. et al. Risk factors for severity and  
525 mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical  
526 Immunology. 2020 Jul 1;146(1):110-8.

- 527 11. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J. et al.  
528 Characteristics and predictors of death among 4035 consecutively hospitalized  
529 patients with COVID-19 in Spain. *Clinical Microbiology and Infection*. 2020 Nov  
530 1;26(11):1525-36.
- 531 12. Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors  
532 Associated with Mortality in COVID-19 Patients: A Systematic Review and Meta-  
533 Analysis. *Iranian journal of public health*. 2020; 49(7), 1211–1221.
- 534 13. Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Sarriá Cabrera MA, Maffei de  
535 Andrade S, Sequí-Dominguez I. et al. Predictors of in-hospital COVID-19 mortality:  
536 A comprehensive systematic review and meta-analysis exploring differences by age,  
537 sex and health conditions. *PloS one*. 2020 Nov 3;15(11): e0241742
- 538 14. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F. et al. The methodological quality  
539 assessment tools for preclinical and clinical studies, systematic review and  
540 meta-analysis, and clinical practice guideline: a systematic review. *Journal of  
541 evidence-based medicine*. 2015 Feb;8(1):2-10
- 542 15. Aromataris E, Munn Z (Editors). *JBI Manual for Evidence Synthesis*. JBI, 2020.  
543 Available from <https://synthesismanual.jbi.global>. [https://doi.org/10.46658/JBIMES-  
544 20-01.#](https://doi.org/10.46658/JBIMES-20-01.#).
- 545 16. Albitar O, Ballouze R, Ooi JP, Ghadzi SM. Risk factors for mortality among COVID-  
546 19 patients. *Diabetes research and clinical practice*. 2020 Aug 1; 166:108293.
- 547 17. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G. et al. Risk  
548 factors associated with mortality among patients with COVID-19 in intensive care  
549 units in Lombardy, Italy. *JAMA internal medicine*. 2020 Oct 1;180(10):1345-55.
- 550 18. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A,  
551 González-Díaz A, Márquez-Salinas A. et al. Predicting mortality due to SARS-CoV-  
552 2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in  
553 Mexico. *The Journal of Clinical Endocrinology & Metabolism*. 2020  
554 Aug;105(8):2752-61.
- 555 19. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H. et al. Obesity and  
556 mortality among patients diagnosed with COVID-19: results from an integrated health  
557 care organization. *Annals of internal medicine*. 2020 Nov 17;173(10):773-81.
- 558 20. Guo A, Lu J, Tan H, Kuang Z, Lou Y, Yang T. et al. Risk Factors on Admission  
559 Associated with Hospital Length of Stay in Patients with COVID-19: A Retrospective  
560 Cohort Study. Available at SSRN 3582769. 2020 Apr 20.

- 561 21. Dahlgren G., Whitehead M. Tackling social inequalities in health. 1993. Available  
562 from: [https://www.euro.who.int/\\_data/assets/pdf\\_file/0018/103824/E89384.pdf](https://www.euro.who.int/_data/assets/pdf_file/0018/103824/E89384.pdf).
- 563 22. Alaa A, Qian Z, Rashbass J, Bengler J, van der Schaar M. Retrospective cohort study  
564 of admission timing and mortality following COVID-19 infection in England. *BMJ*  
565 *open*. 2020 Nov 1;10(11):e042712.
- 566 23. Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F.  
567 et al. Characteristics, risk factors and outcomes among the first consecutive 1096  
568 patients diagnosed with COVID-19 in Kuwait. *EClinicalMedicine*. 2020 Jul 1;  
569 24:100448.
- 570 24. Carrasco-Sánchez FJ, López-Carmona MD, Martínez-Marcos FJ, Pérez-Belmonte  
571 LM, Hidalgo-Jiménez A, Buonaiuto V. et al. Admission hyperglycaemia as a  
572 predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes  
573 status: data from the Spanish SEMI-COVID-19 Registry. *Annals of medicine*. 2021  
574 Jan 1;53(1):103-16.
- 575 25. Halalau A, Imam Z, Karabon P, Mankuzhy N, Shaheen A, Tu J. et al. External  
576 validation of a clinical risk score to predict hospital admission and in-hospital  
577 mortality in COVID-19 patients. *Annals of medicine*. 2021 Jan 1;53(1):78-86.
- 578 26. Kaeuffer C, Le Hyaric C, Fabacher T, Mootien J, Dervieux B, Ruch Y. et al. Clinical  
579 characteristics and risk factors associated with severe COVID-19: prospective  
580 analysis of 1,045 hospitalised cases in North-Eastern France, March 2020.  
581 *Eurosurveillance*. 2020 Dec 3;25(48):2000895.
- 582 27. Okoh AK, Sossou C, Dangayach NS, Meledathu S, Phillips O, Raczek C. et al.  
583 Coronavirus disease 19 in minority populations of Newark, New Jersey. *International*  
584 *journal for equity in health*. 2020 Dec;19(1):1-8.
- 585 28. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y. et al.  
586 Factors associated with hospital admission and critical illness among 5279 people  
587 with coronavirus disease 2019 in New York City: prospective cohort study. *Bmj*.  
588 2020 May 22;369.
- 589 29. Sourij H, Aziz F, Bräuer A, Ciardi C, Clodi M, Fasching P. et al. COVID-19 fatality  
590 prediction in people with diabetes and prediabetes using a simple score upon hospital  
591 admission. *Diabetes, Obesity and Metabolism*. 2020 Nov 16.
- 592 30. Wang Z, Ye D, Wang M, Zhao M, Li D, Ye J. et al. Clinical Features of COVID-19  
593 Patients with Different Outcomes in Wuhan: A Retrospective Observational Study.  
594 *BioMed research international*. 2020 Oct 5;2020.

- 595 31. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z. et al. D-dimer levels on admission to  
596 predict in-hospital mortality in patients with Covid-19. *Journal of Thrombosis and*  
597 *Haemostasis*. 2020 Jun;18(6):1324-9.
- 598 32. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE. et al.  
599 OpenSAFELY: factors associated with COVID-19 death in 17 million patients.  
600 *Nature*. 2020 Jul 8; 584(7821):430-436. DOI: [10.1038/s41586-020-2521-4](https://doi.org/10.1038/s41586-020-2521-4)
- 601 33. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A. et al. Risk  
602 factors for mortality in patients with COVID-19 in New York City. *Journal of general*  
603 *internal medicine*. 2020 Jun 30:1-0.
- 604 34. Wu S, Xue L, Legido-Quigley H, Khan M, Wu H, Peng X. et al. Understanding  
605 factors influencing the length of hospital stay among non-severe COVID-19 patients:  
606 A retrospective cohort study in a Fangcang shelter hospital. *Plos one*. 2020 Oct  
607 21;15(10): e0240959.
- 608 35. Mendy A, Apewokin S, Wells AA, Morrow AL. Factors associated with  
609 hospitalization and disease severity in a racially and ethnically diverse population of  
610 COVID-19 patients. *MedRxiv*. 2020 Jan 1.
- 611 36. van Bavel JJ, Mende-Siedlecki P, Brady WJ, Reiner DA. Contextual sensitivity in  
612 scientific reproducibility. *Proceedings of the National Academy of Sciences*.  
613 2016 Jun; 113 (23) 6454-6459; DOI: [10.1073/pnas.1521897113](https://doi.org/10.1073/pnas.1521897113)
- 614 37. Ioannidis JP, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19  
615 mortality risk for non-elderly individuals overall and for non-elderly individuals  
616 without underlying diseases in pandemic epicenters. *Environmental research*. 2020  
617 Sep 1; 188:109890.
- 618 38. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately  
619 affect older people? *Aging (Albany NY)*. 2020 May 31;12(10):9959.
- 620 39. Chinnadurai R, Ogedengbe O, Agarwal P, et al. Older age and frailty are the chief  
621 predictors of mortality in COVID-19 patients admitted to an acute medical unit in a  
622 secondary care setting- a cohort study. *BMC Geriatrics*. 2020 Oct;20(1):409. DOI:  
623 [10.1186/s12877-020-01803-5](https://doi.org/10.1186/s12877-020-01803-5).
- 624 40. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients.  
625 *Clinical infectious diseases*. 2005 Nov 15;41(Supplement\_7): S504-12.
- 626 41. Mitteldorf J. What is antagonistic pleiotropy? *Biochemistry (Moscow)*. 2019  
627 Dec;84(12):1458-68. <https://doi.org/10.1134/S0006297919120058>

- 628 42. Williams PD, Day T. Antagonistic pleiotropy, mortality source interactions, and the  
629 evolutionary theory of senescence. *Evolution*. 2003 Jul;57(7):1478-88.
- 630 43. Australian Institute of Health. Social Distribution of Health Risks and Health  
631 Outcomes: Preliminary Analysis of the National Health Survey 2007-08. AIHW;  
632 2012.
- 633 44. Eguchi T, Bains S, Lee MC, Tan KS, Hristov B, Buitrago DH. et al. Impact of  
634 increasing age on cause-specific mortality and morbidity in patients with stage I non-  
635 small-cell lung cancer: a competing risks analysis. *Journal of Clinical Oncology*. 2017  
636 Jan 20;35(3):281.
- 637 45. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends  
638 after the first year in survivors of acute myocardial infarction: a systematic review.  
639 *BMC Cardiovascular Disorders*. 2017 Dec;17(1):1-8.
- 640 46. Niccoli T, Partridge L. Ageing as a risk factor for disease. *Current biology*. 2012 Sep  
641 11;22(17): R741-52.
- 642 47. Hernández DS, Verdecia BG. Immunosenescence: effects of aging process on  
643 immune system. *Revista Cubana de Hematología, Inmunología y Hemoterapia*.  
644 2014;30(4):332-45.
- 645 48. Ma Y, Hou L, Yang X, Huang Z, Yang X, Zhao N. et al. The association between  
646 frailty and severe disease among COVID-19 patients aged over 60 years in China: a  
647 prospective cohort study. *BMC medicine*. 2020 Dec;18(1):1-8.
- 648 49. Liu J, Zhang S, Wu Z, Shang Y, Dong X, Li G. et al. Clinical outcomes of COVID-19  
649 in Wuhan, China: a large cohort study. *Annals of intensive care*. 2020 Dec;10(1):1-21.
- 650 50. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features  
651 of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an  
652 observational cohort study. *The Lancet Infectious Diseases*. 2020 Jun 1;20(6):689-96.
- 653 51. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than  
654 men: clinical response to viral infection. *J Biol Regul Homeost Agents*. 2020 Apr  
655 7;34(2):339-43.
- 656 52. Bwire GM. Coronavirus: why men are more vulnerable to Covid-19 than women?.  
657 *SN comprehensive clinical medicine*. 2020 Jul;2(7):874-6.  
658 <https://doi.org/10.1007/s42399-020-00341-w>.
- 659 53. Elgendy IY, Pepine CJ. Why are women better protected from COVID-19: Clues for  
660 men? Sex and COVID-19. *International journal of cardiology*. 2020 Sep 15; 315:105-  
661 6.



- 662 54. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are  
663 males more vulnerable?. *Biology of sex Differences*. 2020 Dec;11(1):1-1.
- 664 55. Marcon G, Tettamanti M, Capacci G, Fontanel G, Spanò M, Nobili A. et al. COVID-  
665 19 mortality in Lombardy: the vulnerability of the oldest old and the resilience of  
666 male centenarians. *Aging (Albany NY)*. 2020 Aug 15;12(15):15186.
- 667 56. De La Vega R, Ruíz-Barquín R, Boros S, Szabo A. Could attitudes toward COVID-19  
668 in Spain render men more vulnerable than women? *Global public health*. 2020 Sep  
669 1;15(9):1278-91.
- 670 57. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate  
671 immunity. *Cold Spring Harbor perspectives in medicine*. 2012 Mar 1;2(3): a007724.
- 672 58. Schulkin J, editor. *Allostasis, homeostasis, and the costs of physiological adaptation*.  
673 Cambridge University Press; 2004 Oct 25.
- 674 59. Oates JR, McKell MC, Moreno-Fernandez ME, Damen MS, Deepe Jr GS, Qualls JE.  
675 et al. Macrophage function in the pathogenesis of non-alcoholic fatty liver disease: the  
676 mac attack. *Frontiers in immunology*. 2019 Dec 12; 10:2893.
- 677 60. Yang P, Gu H, Zhao Z, Wang W, Cao B, Lai C. et al. Angiotensin-converting enzyme  
678 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. *Scientific*  
679 *reports*. 2014 Nov 13;4(1):1-6.
- 680 61. McEwen BS. Sex, stress and the hippocampus: allostasis, allostatic load and the aging  
681 process. *Neurobiology of aging*. 2002 Sep 1;23(5):921-39.
- 682 62. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA. et al.  
683 Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor  
684 blockers on cardiac angiotensin-converting enzyme 2. *Circulation*. 2005 May  
685 24;111(20):2605-10.
- 686 63. Watkins J. Preventing a covid-19 pandemic. *BMJ*. 2020;368:m810.  
687 <https://doi.org/10.1136/bmj.m810>.
- 688 64. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. et al.  
689 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a  
690 clinically proven protease inhibitor. *cell*. 2020 Apr 16;181(2):271-80.
- 691 65. Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD.  
692 Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. *New*  
693 *England Journal of Medicine*. 2020 Apr 23;382(17):1653-9.

- 694 66. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B. et al. A crucial role of angiotensin  
695 converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. *Nature*  
696 *medicine*. 2005 Aug;11(8):875-9.
- 697 67. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of  
698 smoking on COVID-19 severity: A systematic review and meta-analysis. *Journal of*  
699 *Medical Virology*. 2021 Feb;93(2):1045-56.
- 700 68. Katanoda K, Marugame T, Saika K, Satoh H, Tajima K, Suzuki T. et al. Population  
701 attributable fraction of mortality associated with tobacco smoking in Japan: a pooled  
702 analysis of three large-scale cohort studies. *Journal of epidemiology*.  
703 2008:0812050049-.
- 704 69. Centre for Disease Control and Prevention. Tobacco related Mortality. 2020.  
705 Available from:  
706 [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/health\\_effects/tobacco relate](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_relate_d_mortality/index.htm)  
707 [d\\_mortality/index.htm](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_relate_d_mortality/index.htm)
- 708 70. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK. et al. ACE-2  
709 expression in the small airway epithelia of smokers and COPD patients: implications  
710 for COVID-19. *European Respiratory Journal*. 2020 May 1;55(5).
- 711 71. Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, Sheltzer JM.  
712 Cigarette smoke exposure and inflammatory signalling increase the expression of the  
713 SARS-CoV-2 receptor ACE2 in the respiratory tract. *Developmental cell*. 2020 Jun  
714 8;53(5):514-29.
- 715 72. Park J, Lee Y, Seo H, Jang B, Son H, Kim S, Shin S, Hahn S. Risk of Bias  
716 Assessment tool for Non-randomized Studies (RoBANS): Development and  
717 validation of a new instrument. In: *Abstracts of the 19th Cochrane Colloquium; 2011*  
718 *19-22 Oct; Madrid, Spain. John Wiley & Sons; 2011.*

719  
720  
721

722 **Contributors:** SC and NKA conceptualised the research. SC and NKA conducted the  
723 systematic review with inputs from SP. SC wrote the first draft and NKA and SP revised the  
724 manuscript.

725 **Funding:** The authors did not receive any funding for this study from any funding agency in  
726 the public, commercial, or not-for-profit sectors.

727 **Competing interest:** Authors declare no competing interest.

728 **Patient and public involvement:** No direct involvement of patients or the public.

729 **Patient consent for publication:** Not required.

730 **Data availability statement:** All relevant data are either included in this article or added to  
731 the supplementary information.

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767